Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter Study of [18F]APN-1607 Positron Emission Tomography in Subjects With Alzheimer's Disease Compared to Healthy Subjects

NCT05542953 is registered in ClinicalTrials.gov with APRINOIA Therapeutics as lead sponsor.

NCT NCT05542953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05542953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter Study of [18F]APN-1607 Positron Emission Tomography in Subjects With Alzheimer's Disease Compared to Healthy Subjects
Lead sponsor
APRINOIA Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
January 21, 2022
Completion date
December 25, 2023
Enrollment
230 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, healthy volunteers, mild cognitive impairment due to alzheimer's disease